SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending as investors bet on a potential short squeeze and upcoming ecosystem announcements, with the community actively debating whether the project's transition into AI-driven utility will spark a major rally. Despite polarized sentiment between loyalists loading up on dips and skeptics labeling it a pump-and-dump, the stock remains a focal point for those looking to capitalize on volatility within the Base network.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is surging following the FDA's approval of Lumvoa for Thyroid Eye Disease, a milestone that transitions the company to a commercial-stage firm and sets the stage for a competitive launch against existing treatments. Community members are actively debating the company's potential for a buyout, evaluating commercial launch metrics, and analyzing how the company's strong cash position and clinical data compare to its primary market competitors.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is gaining attention as community members debate its long-term potential as a global digital healthcare platform, specifically highlighting recent BetterHelp insurance expansions and a strategic partnership with Walmart. While some investors focus on the stock's massive short interest and institutional accumulation as catalysts for a potential squeeze, others remain cautious, pointing to ongoing leadership scrutiny and the company's path to consistent profitability.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is trending as investors debate the potential success of its merger with Agility Robotics, with sentiment split between excitement over the pure-play robotics opportunity and concerns that it could follow the path of past hyped SPACs. Discussions are heavily focused on the trust redemption rates as a key signal of institutional confidence, while some retail traders remain cautious about the long-term viability of the deal post-merger.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is trending due to its strategic positioning in the physical AI and robotics stack, fueled by recent hardware integration partnerships with industry giants like NVIDIA and LG Innotek. Community discussion is heavily focused on its 4D FMCW LiDAR tech as a foundational sensor for autonomous infrastructure, with traders actively monitoring a recent breakout and evaluating its long-term industrial scaling potential.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is seeing a surge in community engagement driven by its potential role in real-world asset tokenization and broader optimism surrounding upcoming legislative developments. Investors remain divided, with many actively accumulating during price dips, while others express frustration over historical performance and persistent supply dilution.

A composable native asset bridge with unified liquidity and instant guaranteed finality

Stargate

Stargate is gaining momentum as community members track increasing holdings from major exchanges and highlight its role in cross-chain liquidity and DeFi infrastructure. Traders are actively discussing the potential for price volatility while monitoring developments in the broader crypto ecosystem.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

VanEck Gold Miners ETF (GDX) remains a focal point for investors as they weigh the impact of persistent geopolitical uncertainty in the Middle East against shifting macroeconomic signals. The community is actively debating the potential for a rebound, scrutinizing supply-side constraints, and monitoring whether central bank diversification and institutional hedging will provide a structural floor for mining stocks amid broader market volatility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF (SCHD) is currently a focal point for investors navigating a market shift toward defensive, income-focused assets amidst volatility and institutional rotation. Community members are actively debating the fund's role as a long-term anchor for compounding, with discussions highlighting its reliability during sector-specific shocks and the importance of consistent reinvestment in building a structural income foundation.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is trending as investors debate its role as a core infrastructure play for interoperability amid a broader focus on the robotics and physical AI bull run. The community is actively discussing staking rewards and potential regulatory catalysts, while some market participants remain skeptical, leading to polarized views on accumulation versus long-term viability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

Key PointsCEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026...

Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000

Key PointsCMO David Raben sold 5,500 shares of common stock for a transaction value of $126,000 on April 27...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 5,500 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) insider David Raben sold 5,500 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of...

Ivan Hyep Sells 9,200 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 9,200 shares of the company's stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 9,200 Shares of Stock

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 15,000 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 15,000 shares of the business's stock in a transaction on Monday, April 20th. The stock was sold at an average price...

Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 15,000 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 15,000 shares of the business's stock in a transaction dated Monday, April 20th. The shares were sold at an average...

Ryan Cohlhepp Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the business's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average...

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $23.01, for a total value of $287,625.00. Following the sale, the chief operating officer...

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Bicara Therapeutics Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$26.87
Prev Close	$26.34
Open	$26.30
Dividend Yield	0.00%
50-Day Moving Average	$22.08
Beta	1.63
Avg. Volume	522,060.20
PE Ratio	-9.50

52-Week High	$27.98
52-Week Low	$8.58
Market Capitalization	$1.77B
EPS (Annual)	-$2.52
Price to Book	3.36
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCAXBicara Therapeutics

Latest BCAX News